NAFURIL 2 2MG TABLETS

Pays: Chypre

Langue: grec

Source: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

Ingrédients actifs:

GLIMEPIRIDE

Disponible depuis:

DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629

Code ATC:

A10BB12

DCI (Dénomination commune internationale):

GLIMEPIRIDE

Dosage:

2MG

forme pharmaceutique:

TABLETS

Composition:

GLIMEPIRIDE (0093479971) 2MG

Mode d'administration:

ORAL USE

Type d'ordonnance:

Εθνική Διαδικασία

Domaine thérapeutique:

GLIMEPIRIDE

Descriptif du produit:

Νομικό καθεστώς: Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 30 TABS IN BLISTER(S) (280002601) 30 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται

Notice patient

COMPARATIVE TABLE ENGLISH VS GREEK PIL
PACKAGE LEAFLET: INFORMATION FOR THE USER
NAFURIL 1 MG TABLETS
NAFURIL 2 MG TABLETS
NAFURIL 3 MG TABLETS
NAFURIL 4 MG TABLETS
Glimepiride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE
BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their symptoms are the same as
yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See
section 4.
IN THIS LEAFLET:
1.
What Nafuril is and what it is used for
2.
What you need to know before you take Nafuril
3.
How to take Nafuril
4.
Possible side effects
5.
How to store Nafuril
6.
Contents of the pack and other information
ΦΎΛΛΟ ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ: ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ
ΤΟ ΧΡΉΣΤΗ
NAFURIL 1 MG ΔΙΣΚΊΑ
NAFURIL 2 MG ΔΙΣΚΊΑ
NAFURIL 3 MG ΔΙΣΚΊΑ
NAFURIL 4 MG ΔΙΣΚΊΑ
Γλιμεπιρίδη
ΔΙΑΒΆΣΤΕ ΠΡΟΣΕΚΤΙΚΆ ΟΛΌΚΛΗΡΟ ΤΟ ΦΎΛΛΟ
ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ ΠΡΙΝ
ΑΡΧΊΣΕΤΕ ΝΑ ΠΑΊΡΝΕΤΕ ΑΥΤΌ ΤΟ ΦΆΡΜΑΚΟ,
ΔΙΌΤΙ ΠΕΡΙΛΑΜΒΆΝΕΙ ΣΗΜΑΝΤΙΚΈΣ
ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ ΣΑΣ.
•
Φυλάξτε αυτό το φύλλο οδηγιών χρήσης.
Ίσως χρειαστεί να το
διαβάσετε ξανά.
•
Εάν έχετε περαιτέρω απορίες, ρωτήστε
το γιατρό ή το φαρμακοποιό σας.
•
Η συνταγή για αυτό το φάρμακο
χορηγήθηκε αποκλειστικά για σας. Δεν
πρέπει να δώσετε το φάρμακο σε άλλους.
Μπορεί να τους προκαλέσει
βλάβη, ακόμα και όταν τα συμπτώματα
της ασθένειάς τους

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICAL PRODUCT
Nafuril 1 mg Tablets
Nafuril 2 mg Tablets
Nafuril 3 mg Tablets
Nafuril 4 mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
For 1mg strength:
Each tablet contains 1mg of glimepiride.
For 2mg strength:
Each tablet contains 2 mg of glimepiride.
For 3mg strength:
Each tablet contains 3 mg of glimepiride.
For 4mg strength:
Each tablet contains 4 mg of glimepiride.
Excipients: Each tablet contains lactose monohydrate.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets
For 1mg strength:
White, beveled-edge capsule shaped, uncoated tablets
For 2mg strength:
White, beveled-edge capsule shaped, uncoated tablets with breakline on
one side
For 3mg strength:
Yellow coloured, beveled-edge capsule shaped, uncoated tablets with
breakline on one side
For 4mg strength:
Yellow coloured, flat beveled-edge, capsule shaped, uncoated tablets
with breakline on one side
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Nafuril is indicated for the treatment of type 2 diabetes mellitus,
when diet, physical exercise and
weight reduction alone are not adequate.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
For oral administration
1
The basis for successful treatment of diabetes is a good diet, regular
physical activity, as well as
routine checks of blood and urine. Tablets or insulin can not
compensate if the patient does not keep
to the recommended diet.
Posology
Dose is determined by the results of blood and urinary glucose
determinations.
The starting dose is 1 mg glimepiride per day. If good control is
achieved this dose should be used for
maintenance therapy.
For the different dose regimens appropriate strengths are available.
If control is unsatisfactory the dose should be increased, based on
the glycaemic control, in a stepwise
manner with an interval of about 1 to 2 weeks between each step, to 2,
3 or 4 mg glimepiride per day.
A dose of more than 4 mg glimepiride per day gives better results only
in exceptional cases. The
maximum recomme